Comparison
Kisspeptin-10 vs. Pasireotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
374675-21-5
396091-73-9
Molecular weight
1302.44 g/mol
1047.21 g/mol
Half-life
0.07 h
no data
Sequence
H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2no data
Mechanism of action
Kisspeptin-10
Kisspeptin-10 comprises the ten C-terminal amino acids sufficient for binding to the KISS1R receptor (also GPR54). KISS1R is a G-protein-coupled receptor expressed predominantly on GnRH neurons in the hypothalamus. Activation signals through the Gq/11-phospholipase C pathway to release gonadotropin-releasing hormone (GnRH), which in turn drives the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Kisspeptin signaling is regarded as an indispensable trigger of puberty; inactivating mutations in KISS1R are associated with absent puberty (idiopathic hypogonadotropic hypogonadism). Beyond the reproductive axis, KISS1R expression is described in limbic brain regions, discussed as a possible mechanism for the effects on sexual and emotional processing observed in imaging studies.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
1
of which in humans
4
1
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Kisspeptin-10 and Pasireotid?
- Kisspeptin-10 is classified as "Research other", while Pasireotid is classified as "Research other". Kisspeptin-10: Kisspeptin-10 is the shortest bioactive fragment (10 amino acids) of the endogenous neuropeptide kisspeptin, encoded by the KISS1 gene. It acts as an agonist at the KISS1R (GPR54) receptor and stimulates hypothalamic GnRH neurons, driving release of LH and FSH. Kisspeptin is a master switch of puberty and reproduction and is studied in humans, notably by the group of Waljit Dhillo (Imperial College London), in reproductive disorders and in sexual and emotional brain processing. It is not an approved drug. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Kisspeptin-10 or Pasireotid?
- The highest available evidence level is "Human RCT" for Kisspeptin-10 and "Human RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Kisspeptin-10 and Pasireotid in Germany and the United States?
- Germany: Kisspeptin-10 — Unapproved, Pasireotid — Prescription. United States: Kisspeptin-10 — Research only, Pasireotid — Prescription. These are factual summaries with source and review date on the individual pages.